Lv1
28 积分 2024-06-18 加入
Long-Term Stapokibart Treatment Induces Sustained Clinical Improvements in Patients With Moderate-to-Severe Atopic Dermatitis
13小时前
求助中
IL-4, BUT NOT IL-13, MODULATES TARC (THYMUS AND ACTIVATION-REGULATED CHEMOKINE)/CCL17 AND IP-10 (INTERFERON-INDUCED PROTEIN OF 10 kDa)/CXCL10 RELEASE BY TNF-α AND IFN-γ IN HaCaT CELL LINE
3天前
已完结
The differential expression of IL-4 and IL-13 and its impact on type-2 immunity
8天前
已完结
Cytokine profiles in interstitial fluid from chronic atopic dermatitis skin
9天前
已完结
Raising the bar of efficacy in atopic dermatitis: lebrikizumab maintains depth of response over 2 years
22天前
已关闭
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
23天前
已完结
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
23天前
已完结
News beyond our pages
23天前
已关闭
Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab
2个月前
已完结
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
3个月前
已完结
皖公网安备34019202002308
